drugset / Trial / NCT06376045
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Timeline
- Start
- 2024-05-24
- Primary completion
- 2026-05-14
- Completion
- 2026-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rocatinlimab | Monoclonal antibody | — | Subcutaneous |